

INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 1 OF 1

ATTORNEY DOCKET

22660-0025 DIV 2

APPLICATION NO.

09/808,706

APPLICANT(S)

McMillan et al

FILING DATE

March 14, 2001

GROUP


US PATENT DOCUMENTS

† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (if appropriate)
JF	A1	5,219,727	6/1993	Wang et al	435/6	
	A2	5,476,774	12/1995	Wang et al	435/91.2	
	A3	5,710,029	1/1998	Ryder et al	435/911	
	A4	5,747,246	5/1998	Pannetier et al	435/6	
	*A5	5,766,889	6/1998	Atwood	435/91.2	
	A6	5,834,255	11/1998	van Gemen et al.	435/91.21	
	A7	5,837,501	11/1998	Beumer et al.	435/91.2	
	*A8	5,863,736	1/1999	Haaland	435/6	
	A9	6,066,458	5/2000	Haaland	435/6	
	*A10	6,080,574	6/2000	Brendt	435/288.7	
	A11	6,174,670	1/2001	Wittwer et al	435/6	
	A12	6,232,079	5/2001	Wittwer et al	435/6	
	A13	6,294,338	9/2001	Nunomura	435/6	
JZ	A14	6,303,305	10/2001	Wittwer et al	435/6	

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
JZ	*B1	EP0640828 A1	8/1994	EP	
	*B2	WO 97/46707	6/1999	WO	
	B3	EP0497784	7/1999	EP	

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	*C1	LightCycler Operator's Manual Version 3.0, May 1999, Roche Pharmaceuticals
EXAMINER'S SIGNATURE		DATE CONSIDERED
		7-12-02

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).